---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-002394"
form_type: "8-K"
ticker: "EXOZ"
cik: "0002010788"
company_name: "EXOZYMES INC."
filed_at: "2025-04-02T23:59:59+00:00"
generated_at: "2026-05-24T00:06:49.338900+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# eXoZymes appoints Damien Perriman as CCO to lead commercial growth

## Summary
- Damien Perriman appointed to newly created CCO role, effective April 2, 2025.
- Perriman brings 20+ years experience commercializing biotechnologies; previously at Genomatica (Geno) and Gevo.
- Focus on commercial opportunities, spin-outs, joint ventures, and licensing deals with future partners.
- CEO Michael Heltzen: hire reflects strategic focus on scaling and commercializing biosolutions across multiple sectors.

## SEC filing metadata
- accession: 0001641172-25-002394
- form_type: 8-K
- ticker: EXOZ
- cik: 0002010788
- company_name: EXOZYMES INC.
- filed_at: 2025-04-02T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2010788/000164117225002394/0001641172-25-002394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2010788/000164117225002394/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-002394
- JSON: https://secwatch.observer/filing/0001641172-25-002394.json
- Plain text: https://secwatch.observer/filing/0001641172-25-002394.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.